

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

Nerviano Medical Sciences Appointed Paramjit Kaur, PhD to Accelerate PERK/GCN2 Inhibitor Asset Development

NERVIANO, May 17th 2023 – Nerviano Medical Sciences Srl (NMS Srl), a member of NMS Group, the largest oncological R&D company in Italy, focused on the discovering and developing innovative therapies for the treatment of cancer, today announced that Paramjit Kaur, PhD has joined the Global Asset Leadership Team to lead the strategy and the development of clinical PERK/GCN2 asset currently in phase 1.

Dr. Kaur is a highly experienced drug development project leader with proven track record in clinical development, clinical operations, medical affairs, alliance, and project management spanning multiple therapeutic areas and experiences in regulatory filing and product launch experiences.

“We are excited to have Pam join our Asset Leadership Team”, said Alessia Montagnoli, Global Head of Asset Leadership of NMS Srl. “With her strong and wide experience in project leadership in drug development and her proven track record of success, Pam will be invaluable in our driving the rapid advancement of this crucial NMS asset.”

Dr. Kaur commented: “I am excited to lead the PERK/GCN2 asset with first-in-class potential, offering novel treatment options to address high unmet needs of patients. I am delighted to be part of the team that is shaping and implementing NMS’ innovative strategies to the increasingly competitive pipeline.”

Dr. Kaur’s was most recently a Global Asset Leader for the Asparaginases program at Servier, where she brought registration to new formulations of Oncaspar. She previously served as Global Project Leader for Bavencio (anti-PDL1) combinations at EMD Serono (a division of Merck KGaA), within the Pfizer Alliance. Previously, she has held roles in Global Medical Affairs and Clinical Trial Leadership at Alcon Research/Novartis for Ophthalmology, Otic, and Allergy therapeutic areas.

She will be based in Boston, working from the U.S. subsidiary (Nerviano Medical Sciences, Inc./ NMS-US).

About NMS-812

NMS-812 is a potent and selective inhibitor of PERK and GCN2, two key kinases involved in regulating the “integrated stress response” (ISR), a series of signaling pathways that facilitate cellular adaptation to various types of stress conditions and which, importantly, include those commonly encountered by tumor cells. NMS-812 has the potential to be a first-in-class agent targeting the ISR and started patient enrolment in a FIH clinical trial in relapsed/refractory multiple myeloma in mid-2022 (NCT05027594).

About Nerviano Medical Sciences

[Nerviano Medical Sciences](https://www.nervianoms.com) S.r.l. (NMS) is focused on discovery and clinical development of small molecule NCEs for oncology. We take innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Our current pipeline consists of NCEs, which originate from our industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies. Our kinase platform has enabled us to out-license IP rights on approved innovative medicines such as encorafenib and entrectinib and currently includes preclinical to clinical stage products, which are being developed both in house and with partners, including four proprietary clinical assets in Phase I/II studies. Moreover, the

NERVIANO MEDICAL SCIENCES

PART OF NMS GROUP

development of our payload linker platform allows an extension of our pipeline with innovative payload linkers for next generation ADC production.

NMS combines the flexibility of a biotech with the quality of a big pharma. Here, an experienced management team leads a highly skilled staff of professionals with a global vision and a broad range of expertise in drug discovery and development. We collaborate with academia and clinical investigators as well as industrial partners worldwide to advance our programs from early discovery to clinical development of new drugs. The recently signed collaboration agreement with licensing option with Merck Healthcare KGaA for the next-generation highly selective and brain penetrant PARP1 inhibitor NMS-293.

We seek further strategic collaborations to develop and commercialize our products in different territories as well as in-licensing opportunities of promising pre-clinical assets.

About NMS Group

[NMS Group](#) S.p.A. (NMS Group) is the largest R&D company in Italy committed to the discovery and development of novel oncological therapies and through its three subsidiaries is the only institution able to manage the entire integrated R&D chain: from the first steps of the pre-clinical phase to the packaging of the finished product with more than 400 employees of whom more than half are highly educated individuals dedicated to innovative research, development and manufacturing.

NMS Group's three subsidiaries are: NMS S.r.l., focused on discovery and clinical development of new drugs for oncology at Nerviano (Italy) and Boston (US) sites, Accelera S.r.l., one of the few Italian CROs capable of providing support through all phases of drug research and development, and NerPharMa S.r.l., a CDMO owing a wide and cutting edge organizational structure able to manage and handle highly active compounds, and to ensure the full development and production of active principles and finished products.

Media contact: Sidney Dung Sidney.dung@nmsgroup.it